KARACHI (April 27, 2026) — In a decisive move to address the critical shortage of life-saving therapies, the federal government has officially approved the price fixation for 35 new essential drugs. This long-awaited intervention follows a two-year period of regulatory delays that had left patients struggling to access vital treatments. Health Minister Syed Mustafa Kamal successfully presented the case to the federal cabinet, highlighting that the inability to secure official pricing had not only disrupted supply chains but had also forced vulnerable patients to rely on unregulated or smuggled medications. Officials confirmed that an additional 45 pharmaceutical molecules are expected to receive pricing approval in the coming days, further stabilizing the market.
Highlights
- Prices fixed for 35 essential and life-saving medicines to end critical shortages.
- The drugs include high-priority therapies for oncology, organ transplants, cardiovascular diseases, and chronic infections.
- Price fixation covers essential immunizations, including Typhoid Vi, polio, and pneumococcal vaccines.
- The move aims to eliminate reliance on informal, unsafe, and smuggled medicine channels.
- Another 45 pharmaceutical molecules are currently in the pipeline for upcoming clearance.
Approved life-saving drugs, include novel cancer therapies, vaccines and biological products
Read more: https://t.co/IYwB16aozg#GeoNews
— Geo English (@geonews_english) April 27, 2026
Ending the Shortage Cycle
For over two years, the government had deferred price approvals for essential drugs, fearing public perception regarding price increases. However, the resulting lack of availability created a “therapeutic gap” that proved dangerous for patients suffering from cancer, hemophilia, and severe infections. Industry sources noted that the absence of official pricing effectively blocked these medications from entering the formal market, leaving healthcare providers with limited options.
Industry Response
The Pakistan Pharmaceutical Manufacturers’ Association (PPMA) has hailed the decision as a “turning point” for the national healthcare system.
Timely Intervention: Industry leaders expressed relief that the government has prioritized patient care over administrative delays.
Supply Chain Restoration: The move is expected to immediately restore the formal supply chain for advanced treatment options.
By normalizing the availability of these drugs, the government aims to reduce public dependence on unsafe, unregulated alternatives that often lack quality and efficacy verification.
While the government continues its policy of deregulating prices for “non-essential” medicines, this move reaffirms that essential and life-saving drugs will remain under government control to ensure affordability and accessibility for the general public.
You May Like To Read: Traffic restrictions around the Serena Hotel and Red Zone have been lifted – Ishaq Dar
Check out our latest video:
